Back to search

Virginia Commonwealth University

INVESTIGATING SYNERGY BETWEEN RIBONUCLEOTIDE REDUCTASE INHIBITORS AND CMV ANTIVIRALS

Abstract

dc:description.abstract

Cytomegalovirus (CMV) infections remain a significant problem in congenitally infected infants and immunocompromised individuals. Modest antiviral activities of currently approved drugs coupled with dose-limiting toxicities restrict effectiveness and promote development of resistance. The potential for ribonucleotide reductase (RR) inhibitors hydroxyurea (HU), Didox, and Trimidox to synergize, through reduction of nucleotide pools, with the deoxynucleotide analog Ganciclovir (GCV) was examined. A yield reduction assay that utilizes luciferase expressed by a recombinant virus as a surrogate measure of viral infectious units was developed and used to determine effective dose ranges for each drug. RR inhibitors exhibited intrinsic anti-CMV activities on their own with IC50 values well below toxic levels. Moreover, RR inhibitors significantly synergized with GCV. These findings provide a rationale for exploration of RR inhibitors and deoxynucleotide analogs in anti-CMV combination therapy.

Degree

thesis:*
Name thesis:degree_name
Master of Science
Level thesis:degree_level
Thesis
Discipline thesis:degree_discipline
Microbiology & Immunology

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Bhave, Sukhada
Contributors dc:contributor
  • Michael McVoy

Subjects

dc:subject × 3

Rights

dc:rights
Statement dc:rights
  • © The Author

Identifiers

dc:identifier.*

Chain of custody

source
Harvested from
Virginia Commonwealth University
Base URL
scholarscompass.vcu.edu/do/oai/
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Bhave, Sukhada. INVESTIGATING SYNERGY BETWEEN RIBONUCLEOTIDE REDUCTASE INHIBITORS AND CMV ANTIVIRALS. Thesis thesis, https://doi.org/10.25772/CNVY-TJ48